TY - JOUR T1 - The IDentif.AI 2.0 Pandemic Readiness Platform: Rapid Prioritization of Optimized COVID-19 Combination Therapy Regimens JF - medRxiv DO - 10.1101/2021.06.23.21259321 SP - 2021.06.23.21259321 AU - Agata Blasiak AU - Anh T.L. Truong AU - Alexandria Remus AU - Lissa Hooi AU - Shirley Gek Kheng Seah AU - Peter Wang AU - De Hoe Chye AU - Angeline Pei Chiew Lim AU - Kim Tien Ng AU - Swee Teng Teo AU - Yee-Joo Tan AU - David Michael Allen AU - Louis Yi Ann Chai AU - Wee Joo Chng AU - Raymond T.P. Lin AU - David C.B. Lye AU - John Eu-Li Wong AU - Gek-Yen Gladys Tan AU - Conrad En Zuo Chan AU - Edward Kai-Hua Chow AU - Dean Ho Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/29/2021.06.23.21259321.abstract N2 - Objectives We aimed to harness IDentif.AI 2.0, a clinically actionable AI platform to rapidly pinpoint and prioritize optimal combination therapy regimens against COVID-19.Methods A pool of starting candidate therapies was developed in collaboration with a community of infectious disease clinicians and included EIDD-1931 (metabolite of EIDD-2801), baricitinib, ebselen, selinexor, masitinib, nafamostat mesylate, telaprevir (VX-950), SN-38 (metabolite of irinotecan), imatinib mesylate, remdesivir, lopinavir, and ritonavir. Following the initial drug pool assessment, a focused, 6-drug pool was interrogated at 3 dosing levels per drug representing nearly 10,000 possible combination regimens. IDentif.AI 2.0 paired prospective, experimental validation of multi-drug efficacy on a SARS-CoV-2 live virus (propagated, original strain, B.1.351 and B.1.617.2 variants) and Vero E6 assay with a quadratic optimization workflow.Results Within 3 weeks, IDentif.AI 2.0 realized a list of combination regimens, ranked by efficacy, for clinical go/no-go regimen recommendations. IDentif.AI 2.0 revealed EIDD-1931 to be a strong candidate upon which multiple drug combinations can be derived.Conclusions IDentif.AI 2.0 rapidly revealed promising drug combinations for clinical translation. It pinpointed dose-dependent drug synergy behavior to play a role in trial design and realizing positive treatment outcomes. IDentif.AI 2.0 represents an actionable path towards rapidly optimizing combination therapy following pandemic emergence.Highlights- When novel pathogens emerge, the immediate strategy is to repurpose drugs.- Good drugs delivered together in suboptimal combinations and doses can yield low or no efficacy, leading to misperception that the drugs are ineffective.- IDentif.AI 2.0 does not use in silico modeling or pre-existing data.- IDentif.AI 2.0 pairs optimization with prospectively acquired experimental data using a SARS-CoV-2/Vero E6 assay.- IDentif.AI 2.0 pinpoints EIDD-1931 as a foundation for optimized anti-SARS-CoV-2 combination therapies.Competing Interest StatementA. B., E. K-.H. C., and D. H. are co-inventors or previously filed pending patents on artificial intelligence-based therapy development. E. K.-H. C., and D. H. are shareholders of KYAN Therapeutics, which has licensed intellectual property pertaining to AI-based oncology drug development. The findings from this study are being made available for public benefit, and no intellectual property rights arising from the work reported here are being pursued.Funding StatementD. H. gratefully acknowledges support from the Office of the President, Office of the Senior Deputy President and Provost, and Office of the Deputy President for Research and Technology at the National University of Singapore. D. H also gratefully acknowledges funding from the Institute for Digital Medicine (WisDM) Translational Research Programme [grant number R-719-000-037-733] at the Yong Loo Lin School of Medicine, National University of Singapore, Ministry of Education Tier 1 FRC Grant [grant number R-397-000-333-114], Micron Foundation, and Sun Life Singapore. D. H. and E. K.-H. C. gratefully acknowledge the National Research Foundation Singapore under its AI Singapore Programme [Award Number: AISG-GC-2019-002], and Singapore Ministry of Health's National Medical Research Council under its Open Fund- Large Collaborative Grant (OF-LCG) [grant number MOH-OFLCG18May-0028]. E. K.-H. C. is supported by the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence Initiative (Cancer Science Institute of Singapore RCE Main Grant), Ministry of Education Academic Research Fund (MOE AcRF Tier 2 [grant number MOE2019-T2-1-115]), Singapore Ministry of Health's National Medical Research Council under its Open Fund- Large Collaborative Grant (OF-LCG) [grant numbers MOH-OFLCG18May-0023 and MOH-OFLCG18May-0028] and National Research Foundation Competitive Proton Research Programme [grant number NRF-CRP-2017-05]. S. G. K. S., D. H. C., A.P.C.L., G.-Y.G.T. and C. E. Z. C. gratefully acknowledge funding support from Future Systems and Technology Directorate, Singapore Ministry of Defence. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not reflect the views of National Research Foundation, Singapore.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was conducted under study number 2012/00917 approved by the Domain Specific Review Board, as well as approved OSHE/iORC protocol 2020-00494. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData requests can be addressed to the corresponding authors. ER -